title: Monoamines and metabolites in autopsied brain tissue from cirrhotic patients with hepatic encephalopathy.
abstract: Alterations in the metabolism of monoamine neurotransmitters have been proposed to be involved in the development of the hepatic encephalopathy (HE) associated with experimental and human liver failure. In order to evaluate this hypothesis, the monoamines and some of their metabolites were measured in homogenates of caudate nucleus (CAU), prefrontal (PFCo) and frontal cortex (FCo) dissected from brains obtained at autopsy from nine cirrhotic patients who had died in hepatic coma and an equal number of control subjects, free from neurological, psychiatric and hepatic disorders, matched for age and time interval from death to freezing of autopsied brain samples. Monoamine measurements were performed by high-performance liquid chromatography with ion-pairing and electrochemical detection after a simple extraction procedure. In all three regions investigated, concentrations of dopamine (DA) were unchanged in cirrhotic patients vs controls while its metabolites, 3-methoxytyramine (3-MT) and homovanillic acid (HVA) were selectively affected i.e. 3-MT was found to be increased in CAU, while HVA levels were increased in FCo and CAU. DOPAC was also found to be unchanged in CAU. Noradrenaline (NA) levels were greatly increased in PFCo and FCo of cirrhotic patients but remained unchanged in CAU. No significant differences in the concentrations of either serotonin (5-HT) or of its precursor 5-hydroxytryptophan (5-HTP) were found in any of the three regions studied. However, 5-hydroxyindoleacetic acid (5-HIAA), the major metabolite of 5-HT, was increased in PFCo and CAU of cirrhotic patients. These findings show that selective alterations of catecholamine and 5-HT systems are involved in human HE and therefore, they may play an important role in the pathogenesis of certain neurological symptoms associated with this encephalopathy.
authors: Laboratory of Neurochemistry, André-Viallet Clinical Research Centre, Hôpital Saint-Luc, Montréal, Québec, Canada.
authors: M
authors: M
authors: Bergeron
authors: T A
authors: TA
authors: Reader
authors: G P
authors: GP
authors: Layrargues
authors: R F
authors: RF
authors: Butterworth
mesh_terms: D000368:Aged; D015306:Biogenic Monoamines / Q000378:metabolism*; D001921:Brain / Q000378:metabolism*; D002421:Caudate Nucleus / Q000378:metabolism; D002540:Cerebral Cortex / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D004298:Dopamine / Q000031:analogs & derivatives / Q000378:metabolism; D005625:Frontal Lobe / Q000378:metabolism; D006501:Hepatic Encephalopathy / Q000209:etiology / Q000378:metabolism*; D006719:Homovanillic Acid / Q000378:metabolism; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000378:metabolism; D008103:Liver Cirrhosis / Q000150:complications*; D008875:Middle Aged; D009638:Norepinephrine / Q000378:metabolism; D012701:Serotonin / Q000378:metabolism
chemical_list: D015306:Biogenic Monoamines; D012701:Serotonin; D006897:Hydroxyindoleacetic Acid; C001746:3-methoxytyramine; D004298:Dopamine; D009638:Norepinephrine; D006719:Homovanillic Acid